Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra P...

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
...

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2015-03-06

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 71

Registration Number: NCT00023777

Locations: 🇺🇸
MBCCOP - Gulf Coast, Mobile, Alabama, United States
🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸
Veterans Affairs Medical Center - Shreveport, Shreveport, Louisiana, United States

and more 95 locations

Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease

Phase 3

Completed

Conditions: Childhood Mixed Cellularity Classical Hodgkin Lymphoma
Stage I Childhood Hodgkin Lymphoma
Stage IV Childhood Hodgkin Lymphoma
Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma
Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma
Stage II Childhood Hodgkin Lymphoma
Childhood Nodular Sclerosis Classical Hodgkin Lymphoma
Stage III Childhood Hodgkin Lymphoma

Interventions: Biological: Bleomycin Sulfate
Drug: Cyclophosphamide
Drug: Cisplatin
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Cytarabine
Biological: Filgrastim
Drug: Dexamethasone
Radiation: Involved-Field Radiation Therapy
Drug: Prednisone
Drug: Vincristine Sulfate Liposome

First Posted Date: 2003-01-27

Last Posted Date: 2017-04-12

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 1734

Registration Number: NCT00025259

Locations: 🇺🇸
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 172 locations

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 3

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

First Posted Date: 2003-01-27

Last Posted Date: 2010-06-22

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Registration Number: NCT00002517

Locations: 🇫🇷
Centre Hospitalier Regional et Universitaire d'Angers, Angers, France
🇧🇪
Algemeen Ziekenhuis Middelheim, Antwerp, Belgium
🇧🇪
Hopital Universitaire Des Enfants Reine Fabiola, Brussels, Belgium

and more 20 locations

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma

Phase 2

Completed

Conditions: Leukemia
Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2010-06-11

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 3

Registration Number: NCT00047021

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

Phase 3

Conditions: Leukemia
Myelodysplastic Syndromes

First Posted Date: 2003-01-27

Last Posted Date: 2010-05-27

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 80

Registration Number: NCT00002926

Locations: 🇧🇪
Hopital Universitaire Erasme, Brussels, Belgium
🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇨🇿
Institute of Hematology and Blood Transfusion, Prague, Czech Republic

and more 37 locations

Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia

Phase 3

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2009-12-23

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 2000

Registration Number: NCT00004128

Combination Chemotherapy and Total-Body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2011-11-30

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00027547

Locations: 🇺🇸
Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States
🇩🇪
Universitaet Leipzig, Leipzig, Germany
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma

Phase 3

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: German Hodgkin's Lymphoma Study Group

Target Recruit Count: 220

Registration Number: NCT00025636

Locations: 🇧🇪
Ziekenhuis Netwerk Antwerpen Middelheim, Antwerp, Belgium
🇩🇪
Universitaetsklinikum Essen, Essen, Germany
🇩🇪
Klinik Fuer Innere Medizin, Hematology/Oncology, Ernst Moritz Armdt Universitaet, Greifswald, Germany

and more 41 locations

Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Biological: rituximab
Drug: carmustine
Drug: cyclophosphamide
Drug: cytarabine
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: leucovorin calcium
Drug: methotrexate
Drug: prednisone
Drug: vincristine sulfate
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-01-27

Last Posted Date: 2016-07-19

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 79

Registration Number: NCT00020943

Locations: 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸
Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Ellis Fischel Cancer Center at University of Missouri - Columbia, Columbia, Missouri, United States

and more 78 locations

Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma

Phase 3

Completed

Conditions: Lymphoma

Interventions: Drug: asparaginase
Drug: cyclophosphamide
Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: leucovorin calcium
Drug: mercaptopurine
Drug: methotrexate
Drug: prednisone
Drug: thioguanine
Drug: vincristine sulfate
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2019-08-06

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 393

Registration Number: NCT00004228

Locations: 🇺🇸
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States
🇺🇸
Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸
MBCCOP - Medical College of Georgia Cancer Center, Augusta, Georgia, United States

and more 172 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy